|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 47/68 | |
| A61K 38/17 | |||
| A61P 7/06 |
| (11) | Patento numeris | 2303917 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09770553.7 |
| Europos patento paraiškos padavimo data | 2009-06-26 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-04-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-11-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2009/003808 |
| Data | 2009-06-26 |
| (87) | Numeris | WO 2009/158015 |
| Data | 2009-12-30 |
| (30) | Numeris | Data | Šalis |
| 133368 P | 2008-06-26 | US |
| (72) |
SHERMAN, Matthew, L., US
SEEHRA, Jasbir, US
BORGSTEIN, Niels, US
|
| (73) |
Acceleron Pharma Inc.,
128 Sidney Street, Cambridge, MA 02139,
US
|
| (54) | ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS |
| ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS |